FemmePharma, Inc. was formed by Gerianne Tringali-DiPiano in 1996 to target identifiable unmet needs within the women's healthcare pharmaceutical market. The Company has a number of drugs in development based on its PARDEL technology. FemmePharma, Inc. is devoted to developing safe and effective drugs that minimize or eliminate unpleasant side effects associated with many medications by designing them in a manner that is specifically suited to a women's physiology, with an eye toward the changing needs of women throughout their lives. The Company has a number of drugs in development based on its proprietary technologies including new therapeutic options for fibrocystic breast disease.
